New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
07:15 EDTEWEdwards Lifesciences shares should be bought on weakness, says Wells Fargo
After Edwards reported lower than expected U.S. Q4 Sapien revenue, Wells Fargo thinks that a large number of catalysts should cause the stock to outperform for the remainder of 2013. The firm maintains an Outperform rating on the stock.
News For EW From The Last 14 Days
Check below for free stories on EW the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
17:53 EDTEWEdwards says not looking for complete ban of Medtronic valve, Bloomberg says
Subscribe for More Information
April 15, 2014
09:23 EDTEWBarclays medical supplies/devices analysts hold analyst/industry conference call
Subscribe for More Information
April 14, 2014
16:24 EDTEWOn The Fly: Closing Wrap
Subscribe for More Information
12:26 EDTEWOn The Fly: Midday Wrap
Subscribe for More Information
12:00 EDTEWEdwards Lifesciences rises 13.7%
Edwards Lifesciences is up 13.7%, or $10.01, to $82.98
10:51 EDTEWEdwards up after court limits sale of Medtronic's CoreValve in U.S.
Subscribe for More Information
10:30 EDTEWHigh option volume stocks: ZLTQ GLOG RHT SBAC EW
Subscribe for More Information
10:25 EDTEWEdwards Lifesciences rises sharply following court action, upgrades
Subscribe for More Information
10:00 EDTEWEdwards Lifesciences rises 13.9%
Subscribe for More Information
09:00 EDTEWEdwards Lifesciences rises 11.3%
Edwards Lifesciences is up 11.3%, or $8.28, to $81.25
08:59 EDTEWOn The Fly: Pre-market Movers
Subscribe for More Information
08:12 EDTEWEdwards Lifesciences price target raised to $90-$91 from $82-$83 at Wells Fargo
Wells Fargo increased its price target on Edwards after a federal court granted a preliminary injunction limiting the sale of a competing product, Medtronic's (MDT) CoreValve. The firm said the injunction was a "major surprise," and estimates that the injunction could increase Edwards EPS by 15c in 2014 and 34c in 2015. Wells keeps an Outperform rating on the stock.
07:39 EDTEWEdwards Lifesciences upgraded to Buy from Fair Value at CRT Capital
Subscribe for More Information
06:22 EDTEWMedtronic downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
06:21 EDTEWEdwards Lifesciences upgraded to Neutral from Underweight at JPMorgan
Subscribe for More Information
April 13, 2014
15:10 EDTEWMedtronic says CoreValve ruling has no impact outside U.S.
Subscribe for More Information
April 12, 2014
19:50 EDTEWEdwards says court limits sale of Medtronic CoreValve system in U.S.
Edwards Lifesciences (EW) announced that the U.S. District Court for the District of Delaware granted a preliminary injunction limiting the sale of Medtronic's (MDT) CoreValve system in the United States. The court ordered the injunction to go into effect in seven business days. The hearing related to a federal jury decision in 2010 that CoreValve willfully infringes Edwards' U.S. Andersen transcatheter aortic valve replacement patent. At the conclusion of the hearing, Chief Judge Gregory Sleet ordered Edwards and Medtronic to confer on what instances the CoreValve device could continue to be used in the treatment of U.S. patients at centers currently trained on CoreValve. There is a large body of evidence demonstrating the safety and performance of the Edwards SAPIEN valves, and the company remains committed to ensuring patients have appropriate access to transcatheter therapy. This case was initiated by Edwards in 2008. On April 1, 2010, a federal jury found Medtronic willfully infringed Edwards' U.S. Andersen patent and awarded damages. In Nov. 2012, the U.S. Court of Appeals for the Federal Circuit affirmed the jury decision; in Oct. 2013, the U.S. Supreme Court declined to hear Medtronic's appeal. The patent involved in this suit is part of the Andersen family of patents. The U.S. Andersen patent was issued in 1995. A petition has been filed with the U.S. Patent and Trademark Office to extend this patent into early 2016. In a separate case, a federal jury in January found that Medtronic CoreValve had willfully infringed Edwards' U.S. Cribier transcatheter heart valve patent, and awarded damages to Edwards in that trial.
April 8, 2014
07:26 EDTEWElsevier Business Intelligence to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use